DNage To Participate in EU Study on Biomarkers of Aging | GenomeWeb
NEW YORK (GenomeWeb News) – DNage, a wholly owned subsidiary of Dutch biotech Pharming Group, said today that it will participate in a five-year European study that aims to identify biomarkers of human aging.
 
The project, called MARK-AGE, is an EU-wide consortium of 26 industry and academic partners funded under the Seventh Research Framework Program. The EU has awarded a total of around €12 million ($19 million) for the study. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.